258818-34-7
258818-34-7 structure
- Name: Larazotide
- Chemical Name: 2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid
- CAS Number: 258818-34-7
- Molecular Formula: C32H55N9O10
- Molecular Weight: 725.83300
- Catalog: Signaling Pathways Cytoskeleton Gap Junction Protein
- Create Date: 2018-08-25 20:53:18
- Modify Date: 2024-01-05 10:19:40
-
Larazotideis a peptide which is an orally active zonulin antagonist. Larazotide shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide can be used for the research of celiac disease and infection[1][2].
| Name | 2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid |
|---|---|
| Synonyms |
UNII-ZN3R5560ZV
AT-2347 Larazotide |
| Description | Larazotideis a peptide which is an orally active zonulin antagonist. Larazotide shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide can be used for the research of celiac disease and infection[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Larazotide (1-100 μM; 5 d) affects Vero cell growth[1]. Larazotide (1-100 μM; 3 d) shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively[1]. Larazotide (1 and 3 mM; 72 h) inhibits cytokine-induced tight junction permeability in Caco-2 cells[2]. Larazotide (100 μM; 3 h) inhibits gliadin translocation across Caco-2 monolayers[2]. Larazotide (12.5 mM; 1 h) inhibits PTG-induced ZO-1 redistribution and actin cytoskeletal rearrangement in IEC6 cells[2]. Cell Cytotoxicity Assay[1] Cell Line: Vero cell line Concentration: 1-100 μM Incubation Time: 5 days Result: Inhibited Vero cell growth with an CC50 value of 82.5 μM. |
| In Vivo | Larazotide (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice[1]. Animal Model: HLA-HCD4/DQ8 double transgenic mice[2] Dosage: 250 μg Administration: Intraperitoneal injection; 250 μg twice a week for 7 weeks Result: Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels. |
| Density | 1.254 |
|---|---|
| Molecular Formula | C32H55N9O10 |
| Molecular Weight | 725.83300 |
| Exact Mass | 725.40700 |
| PSA | 301.32000 |
| LogP | 0.49980 |